Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib in Pediatric Solid Tumors
NCT04236414Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Jan 2020
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 1, open-label trial of olaparib in solid tumor (4 arms), sponsored by AstraZeneca. Primary endpoints: Dose Limiting Toxicity at 28 days and Safety and Tolerability. Started Jan 2020; status: completed.
02
Drugs
olaparib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04236414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04236414.